WO2021028640A1 - Comprimé orodispersible d'opioide à faible dosage et son procédé de préparation - Google Patents
Comprimé orodispersible d'opioide à faible dosage et son procédé de préparation Download PDFInfo
- Publication number
- WO2021028640A1 WO2021028640A1 PCT/FR2020/051464 FR2020051464W WO2021028640A1 WO 2021028640 A1 WO2021028640 A1 WO 2021028640A1 FR 2020051464 W FR2020051464 W FR 2020051464W WO 2021028640 A1 WO2021028640 A1 WO 2021028640A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- opioid
- agent
- granules
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the present invention relates to an oral pharmaceutical form of an opioid, in particular morphine and its salts, for immediate release at low dosage and its method of preparation.
- Opioids and in particular morphine are used for the treatment of moderate to severe pain. Morphine is also used for the treatment of chronic pain.
- Orodispersible tablets or ODT represent a booming dosage form, which has developed a lot in recent years.
- orodispersible tablets have many advantages and are particularly suitable for patients with swallowing difficulties, for example children and the elderly.
- these populations are not the only ones to present with dysphagia, as approximately 30 to 50% of the population is affected by this problem.
- Orodispersible tablets are also suitable for people who do not have easy access to water, especially when traveling. Another advantage of said tablets is that they allow convenient and discreet use.
- orodispersible tablets remain a fairly widespread form and appreciated by patients, in particular for their practical and rapid use, a study carried out by the Applicant has shown that the taste and the sensation in the mouth of a tablet appear to be the most important parameters for patients, and therefore bad taste and / or unpleasant sensation in the mouth, are one of the major causes of non-compliance with medical treatments, and therefore of their non-success.
- orodispersible tablets are porous in structure and are compressed at lower pressures than conventional tablets, the disadvantages being that they can be more fragile and difficult to handle.
- Patent application WO 00/06126 in the name of TAKEDA CHEMICAL INDUSTRIES discloses an ODT form which may contain an active principle which is not an opioid, a sugar and between 5 to 7% of hydroxypropyl cellulose. The amount of active principle is 0.01 and 70 parts by weight. ODT tablets are made from coated granules.
- Patent application WO 00/78292 in the name of TAKEDA CHEMICAL INDUSTRIES discloses an ODT form which may contain morphine in its nucleus and produced from mannitol.
- the amount of active principle is between 0.01 and 70 parts by weight.
- the application also discloses the use of microcrystalline cellulose as a binder, crospovidone as a disintegrant.
- Patent application WO 2009/086046 filed by Eurand Inc. discloses an ODT form which may contain morphine in its nucleus.
- the application also discloses povidone or HPC as a binder, crospovidone as a disintegrant, microcrystalline cellulose as a diluent and magnesium stearate as a lubricant.
- Patent application WO 2007/141328 in the name of the Applicant describes sublingual tablets containing a low dose of active principle coated on a core.
- Low dosage of active principle is called a dosage of 0.1 to 5%, preferably from 0.2 to 3% and more preferably still from 0.5 to 1, 5% by mass of active principle relative to the total mass of the tablet with a content of active principle per tablet of 7 to 0.5 mg, preferably 5.5 to 1.5 mg, more preferably still of approximately 5 mg, 2, 5 mg or 1 mg.
- a low dosage opioid orodispersible tablet comprising:
- a given amount of magnesium stearate and of a silica having a high affinity for aqueous media such as a colloidal silica, a precipitated silica, or a mixture of colloidal silica and precipitated silica, preferably a precipitated silica, to improve the homogeneity of the orodispersible tablet with a low dosage of opioid.
- the present invention relates to a low dosage opioid orodispersible tablet comprising:
- an orodispersible tablet is a tablet which disintegrates or disintegrates in the mouth, only on contact with saliva, without water supply and without being chewed, in less than 60 seconds, of preferably in less than 40 seconds, and more preferably still in less than 30 seconds, forming an easy to swallow suspension.
- the disintegration time (or disintegration) in the mouth corresponds to the time which separates, on the one hand, the moment of the placement of the tablet in the mouth in contact with saliva and, on the other hand, the moment of swallowing of the suspension resulting from the disintegration (disintegration) of the tablet in contact with saliva. This disintegration time corresponds to the disintegration time in vivo.
- disintegration time in vitro of the orodispersible tablets according to the invention.
- This disintegration time is measured according to European Pharmacopoeia 2.9.1 on an Erweka ZT 301 device or any other device for measuring the disintegration time of tablets, corresponding to European Pharmacopoeia 2.9.1.
- the in vitro disintegration time of the tablets according to the invention is 10 to 20 seconds.
- the granules of the present invention relate to agglomerates of particles, which comprise an opioid as an active ingredient, a diluent and a binder.
- the opioid is selected from morphine, bupremorphine, desomorphine, dihydromorphine, hydrocodone, hydromorphone, methadone, oxycodone, oxymorphone.
- the opioid may be in the free form or in the form of an ester, salt, hydrate, solvate, polymorph, isomer, or other pharmaceutically acceptable forms.
- the invention is very particularly suitable for morphine or morphine sulfate.
- morphine sulfate or “morphine sulfate” will be used without distinction.
- the opioid is present in the granules in an amount of 8 to 27%, preferably 15 to 25% and more preferably still about 20% by weight relative to the total weight of the granules.
- the diluent present in the granules is a pharmaceutically acceptable diluent which is soluble and is chosen from mannitol, microcrystalline cellulose and their mixtures.
- the binder present in the granules is a pharmaceutically acceptable binder, preferably a cellulose derivative, in particular hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxyethylcelllulose, and mixtures thereof.
- the ratio by weight between the diluent and the binder in the granules is from 20: 1 to 10: 1, preferably from 15: 1.
- the granules of the present invention can be obtained by a process known per se such as, for example, extrusion-spheronization, wet or hot granulation.
- the granules are present in the orodispersible tablet in an amount of 10 to 30%, preferably 15 to 25%, more preferably about 20% by mass of the total mass of the tablet. Below 10%, it is difficult to obtain good homogeneity of the active principle. Above 30%, the disintegration time of the tablet is reduced and the mouth feel is not very satisfactory.
- the orodispersible tablet also comprises a mixture of compression excipients.
- a diluting agent present in the mixture of compression excipients is chosen from microcrystalline cellulose, a polyol of less than 13 carbon atoms, in particular mannitol, xylitol, sorbitol and / or maltitol, or mixtures thereof
- the diluting agent is either in the form of the directly compressible product whose average particle diameter is 100 to 500 ⁇ m, or in the form of a powder whose average particle diameter is less than 100 ⁇ m.
- the proportion of diluting agent used for the constitution of the orodispersible tablet relative to the mass of the tablet is 30 to 90% by mass.
- the disintegrating agent also called disintegrating or disintegrating agent, is chosen from the group comprising in particular crosslinked sodium carboxymethylcellulose designated in the art by the term croscarmellose, crospovidone and their mixture. Thanks to the choice and the proportion of this disintegrating agent, the tablet maintains an acceptable hardness for normal handling conditions of the tablets when they are stored in sealed packaging up to temperatures of at least 30 ° C.
- the proportion of disintegrating agent used for the constitution of the orodispersible tablet is from 1 to 15% by mass, preferably from 2 to 10% by mass and more preferably about 5% by mass relative to the mass of the tablet.
- the lubricant preferentially used in this mixture of excipients is chosen from the group comprising magnesium stearate, sodium stearyl fumarate, stearic acid, micronized polyethylene glycol (micronized Macrogol 6000), and mixtures thereof II can be used in a proportion of 1 to 2% by mass relative to the total mass of the tablet.
- magnesium stearate is used.
- An amount less than 1% may be insufficient in industrial conditions, in particular for low dosages and cause sticking phenomena.
- An amount greater than 2% increases the disintegration time of the tablet.
- permeabilizing agent use is made of a compound chosen from the group comprising in particular silicas having a high affinity for aqueous solvents, such as colloidal silicas, precipitated silicas, for example precipitated silicas known under the trade name Sylo ⁇ d®. , maltodextrins, ⁇ -cyclodextrins and their mixtures.
- the permeabilizing agent is chosen from precipitated silica, colloidal silica, and their mixtures, and even more advantageously, the permeabilizing agent is a silica rushed.
- these silicas contribute to better disintegration of the tablets, but also, by virtue of their permeabilizer / flow agent properties, they promote particle rearrangements during compression and they make it possible to to reduce, on the one hand, the quantity of hydrophobic lubricant necessary to ensure the manufacture under optimal conditions and, on the other hand, to reduce the intensity of the compressive force to obtain a tablet which can be handled under industrial conditions.
- the proportion of permeabilizing agent relative to the mass of the tablet is between 0.5 and 5% by mass, preferably from 1 to 2.5% by mass relative to the total mass of the tablet.
- the ratio by weight of the lubricant to the permeabilizer is greater than or equal to 1.
- the mixture of excipients entering into the composition of the tablets according to the invention can also comprise a sweetener, a flavoring and a colorant.
- the sweetener can be chosen from the group comprising in particular aspartame, potassium acesulfame, sodium saccharinate, neohesperidin dihydrochalcone, and mixtures thereof.
- the flavors and colorings are those usually used in pharmacies for the preparation of tablets.
- the tablets according to the invention have, compared to tablets of the type in question which already exist, an improvement in palatability and in particular in taste and texture and can make it possible to reduce the mass ratio of the tablet / dose of active ingredient.
- the tablet according to the invention comprises:
- sweetener 0 to 5% sweetener, flavoring and / or coloring, the percentages being by mass relative to the total mass of the tablet.
- the invention also relates to a process for preparing an orodispersible tablet as described above comprising:
- the granules are prepared as follows:
- a step of mixing the active principle, the diluent and the binder is carried out at a blade speed of between 200 and 80 rpm (rotation per minute), preferably between 170 and 110 rpm and more preferably still of 140 rpm at a temperature between 30 and 10 ° C, preferably between 25 and 15 ° C, and more preferably still at 20 ° C.
- the duration of this step is between 500 and 75 seconds, preferably between 400 and 150 seconds and more preferably still of 300 seconds so as to obtain a homogeneous mixture.
- a wetting step is then carried out according to the general knowledge of those skilled in the art depending on the amount of raw material used.
- a granulation step is carried out at a blade speed of between 170 and 50 rpm (rotation per minute), preferably between 140 and 80 rpm and more preferably still of 110 rpm at a temperature between 30 and 10 ° C, from preferably between 25 and 15 ° C, and more preferably still at 20 ° C, the lump breaker speed is between 1500 and 500 rpm, preferably between 1250 and 750 rpm, and more preferably still at 1000 rpm,
- the grains obtained by granulation are dried to a temperature of between 40 and 24 ° C, preferably between 36 and 28 ° C, and more preferably still at 32 ° C. Drying continues until a drying loss of less than 3.00% is achieved. This loss on drying is achieved by means of a Mettler HR 73 thermobalance (10 minutes at 105 ° C).
- a step of reducing the size of the particles is then carried out by means of grinding (knife / hammer mill or conical mill), followed by sieving through a screen having an opening of 1100 ⁇ m to 100 ⁇ m, of preferably between 800 pm and 200 pm and even more preferably 500 pm
- the mixture of compression excipients is prepared with the exception of the lubricant.
- the granules can also be mixed with part of the compression excipients and then add the remaining excipients.
- the lubrication step is carried out as follows.
- the total quantity of lubricant, preferably of magnesium stearate is added to the mixture carried out previously, the lubrication is carried out with a speed of rotation of between 1 and 20 rpm, preferably between 5 and 15 rpm and more preferably still 10 rpm for 1 to 12 minutes, preferably 3 to 9 minutes and more preferably still 6 minutes depending on the mass of the mixture.
- the compression step is carried out on a rotary machine adjusted in order to obtain tablets having the given target characteristics of mass and hardness.
- the invention relates to the use of 1 to 2% of lubricant and of a permeabilizing agent in a lubricant / permeabilizing agent ratio> 1, to improve the homogeneity of the opioid active principle of an orodispersible tablet low dose, the% being by mass relative to the mass of the orodispersible tablet.
- the examples below provide a better understanding of the invention. They are given by way of illustration only but are not limiting.
- Orodispersible tablets of morphine sulfate dosed at 1 mg, 2.5 mg and 5 mg are prepared.
- a step of mixing the following raw materials is carried out: HPC-SL, Mannitol 60 PhE, Morphine Sulfate, at a blade speed of 140 rpm at a temperature of approximately 20 ° C.
- the duration of this step is 300 seconds so as to obtain a homogeneous mixture.
- a step of wetting the above mixture is carried out by means of a peristaltic pump.
- the duration of this step is 1 to 10 minutes, preferably 2 to 5 minutes and more preferably still 3 minutes.
- the granulation is carried out at a blade speed of 110 rpm and at a temperature of 20 ° C, the lump breaker speed is 1000 rpm,
- the duration of the granulation step is about 60 seconds.
- the grains obtained are dried at a temperature of 32 ° C. Drying continues until a drying loss of less than 3.00% is achieved.
- the granules then undergo a size reduction step by means of a mill through a grid having an opening of 500 ⁇ m.
- the speed of rotation of the tank is set at 10 rpm for 1 to 20 minutes, preferably 5 to 15 minutes and more preferably still 10 minutes.
- the total amount of magnesium stearate is added to the mixture carried out previously, the lubrication is carried out with a rotational speed of 10 rpm for 6 minutes.
- the average disintegration time in the mouth was 40 seconds.
- Example 2 The procedure is as for Example 1, with the compositions given in Table 7 below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080056910.5A CN114258300A (zh) | 2019-08-13 | 2020-08-13 | 低剂量口分散阿片类药物片剂及其制备方法 |
AU2020329628A AU2020329628A1 (en) | 2019-08-13 | 2020-08-13 | Low-dosage orodispersible opioid tablet and method for preparing same |
EP20772360.2A EP4013386A1 (fr) | 2019-08-13 | 2020-08-13 | Comprimé orodispersible d'opioide à faible dosage et son procédé de préparation |
US17/634,684 US20220296507A1 (en) | 2019-08-13 | 2020-08-13 | Low-dosage orodispersible opioid tablet and method for preparing same |
CA3149554A CA3149554A1 (fr) | 2019-08-13 | 2020-08-13 | Comprime orodispersible d'opioide a faible dosage et son procede de preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1909185A FR3099881B1 (fr) | 2019-08-13 | 2019-08-13 | Comprimé orodispersible d’opioide à faible dosage et son procédé de préparation. |
FRFR1909185 | 2019-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021028640A1 true WO2021028640A1 (fr) | 2021-02-18 |
Family
ID=68654740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2020/051464 WO2021028640A1 (fr) | 2019-08-13 | 2020-08-13 | Comprimé orodispersible d'opioide à faible dosage et son procédé de préparation |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220296507A1 (fr) |
EP (1) | EP4013386A1 (fr) |
CN (1) | CN114258300A (fr) |
AU (1) | AU2020329628A1 (fr) |
CA (1) | CA3149554A1 (fr) |
FR (1) | FR3099881B1 (fr) |
WO (1) | WO2021028640A1 (fr) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006126A1 (fr) | 1998-07-28 | 2000-02-10 | Takeda Chemical Industries, Ltd. | Preparation solide a desintegration rapide |
WO2000078292A1 (fr) | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Preparations solides a desintegration rapide |
WO2001019336A1 (fr) | 1999-09-15 | 2001-03-22 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
WO2001080822A2 (fr) * | 2000-04-20 | 2001-11-01 | Ethypharm | Granules effervescents et techniques de preparation |
WO2007141328A1 (fr) | 2006-06-09 | 2007-12-13 | Ethypharm | Comprimés faiblement dosés d'analgésiques opioïdes et leur procédé de préparation. |
WO2009086046A1 (fr) | 2007-12-21 | 2009-07-09 | Eurand, Inc. | Compositions de comprimé de temazépam à désintégration orale |
CN103860499A (zh) * | 2014-03-25 | 2014-06-18 | 王媛媛 | 一种盐酸美沙酮口腔崩解片及其制备方法 |
CN103877047A (zh) * | 2014-03-25 | 2014-06-25 | 王媛媛 | 一种盐酸羟考酮分散片及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
-
2019
- 2019-08-13 FR FR1909185A patent/FR3099881B1/fr active Active
-
2020
- 2020-08-13 WO PCT/FR2020/051464 patent/WO2021028640A1/fr unknown
- 2020-08-13 EP EP20772360.2A patent/EP4013386A1/fr active Pending
- 2020-08-13 US US17/634,684 patent/US20220296507A1/en active Pending
- 2020-08-13 CA CA3149554A patent/CA3149554A1/fr active Pending
- 2020-08-13 AU AU2020329628A patent/AU2020329628A1/en active Pending
- 2020-08-13 CN CN202080056910.5A patent/CN114258300A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000006126A1 (fr) | 1998-07-28 | 2000-02-10 | Takeda Chemical Industries, Ltd. | Preparation solide a desintegration rapide |
WO2000078292A1 (fr) | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Preparations solides a desintegration rapide |
WO2001019336A1 (fr) | 1999-09-15 | 2001-03-22 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
WO2001080822A2 (fr) * | 2000-04-20 | 2001-11-01 | Ethypharm | Granules effervescents et techniques de preparation |
WO2007141328A1 (fr) | 2006-06-09 | 2007-12-13 | Ethypharm | Comprimés faiblement dosés d'analgésiques opioïdes et leur procédé de préparation. |
WO2009086046A1 (fr) | 2007-12-21 | 2009-07-09 | Eurand, Inc. | Compositions de comprimé de temazépam à désintégration orale |
CN103860499A (zh) * | 2014-03-25 | 2014-06-18 | 王媛媛 | 一种盐酸美沙酮口腔崩解片及其制备方法 |
CN103877047A (zh) * | 2014-03-25 | 2014-06-25 | 王媛媛 | 一种盐酸羟考酮分散片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US20220296507A1 (en) | 2022-09-22 |
FR3099881B1 (fr) | 2022-08-26 |
CA3149554A1 (fr) | 2021-02-18 |
AU2020329628A1 (en) | 2022-03-03 |
EP4013386A1 (fr) | 2022-06-22 |
FR3099881A1 (fr) | 2021-02-19 |
CN114258300A (zh) | 2022-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2350054C (fr) | Comprime a delitement rapide perfectionne | |
EP1385489B1 (fr) | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'angiotensine | |
TWI326602B (en) | Guaifenesin sustained release formulation and tablets | |
JP4965130B2 (ja) | 乾式直打速崩壊性錠剤 | |
FR2883179A1 (fr) | Comprime enrobe | |
CA2528249C (fr) | Comprime orodispersible multicouche | |
JP2001510785A (ja) | 速崩壊性口内溶解錠の製造に適した顆粒の製造方法 | |
BE1015217A5 (fr) | ||
JP2000504028A (ja) | 口内薬剤輸送系 | |
EA019614B1 (ru) | Усовершенствованная фармацевтическая композиция, содержащая антагонист дигидропиридинкальциевого канала, и способ ее получения | |
OA10336A (fr) | Association thérapeutique vitamino-calcique sous forme galénique unitaire de comprimés son procédé d'obtention et son utilisation | |
RU2174837C2 (ru) | Быстрораспадающаяся готовая препаративная форма трамадола или соли трамадола | |
FR2850576A1 (fr) | Composition comprenant un melange de principes actifs, et procede de preparation | |
FR2850577A1 (fr) | Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules | |
FR2858556A1 (fr) | Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation | |
EP1549326A1 (fr) | Formulation orale seche a visee phlebotonique et vasculoprotectrice pour le traitement de l'insuffisance veineuse, de la fragilite capillaire et de la crise hemorroidaire, sous forme pharmaceutique de comprime a croquer contenant de la diosmine | |
WO2010001574A1 (fr) | Procédé de production de microparticules sphériques comprenant du chlorhydrate de tamsulosine | |
US8906949B2 (en) | Orally disintegrating tablets of zolmitriptan and process for preparing the same | |
JP2010241760A (ja) | 不快な味の軽減された口腔内速崩壊錠及びその製造方法 | |
EP4013386A1 (fr) | Comprimé orodispersible d'opioide à faible dosage et son procédé de préparation | |
EP2931257B1 (fr) | Comprimes orodispersibles obtenus par compression moulage | |
CA3085219A1 (fr) | Formulation de film comprenant du vardenafil, procede pour sa preparation et son utilisation | |
JP2005060309A (ja) | 不快な味を低減した口腔内崩壊錠剤 | |
WO2020246120A1 (fr) | Comprimé à désintégration buccale et son procédé de production | |
WO2001085134A1 (fr) | Compositions pharmaceutiques solides et procede de production de comprimes se dissolvant dans la bouche |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20772360 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3149554 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020329628 Country of ref document: AU Date of ref document: 20200813 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020772360 Country of ref document: EP Effective date: 20220314 |